https://www.selleckchem.com/pr....oducts/4-phenylbutyr
5% (n=24) of cases. Cases did not differ significantly from controls regarding CYP3A4, CYP2C9, or OATP1B1 phenotypes, and genetic variation explained only 20.6% (n=7) of cases. Withdrawal of simvastatin without switching to another statin or with a switch to a hydrophilic statin led to improvement or stabilization in all NSIP cases, whereas all cases who were switched to the lipophilic atorvastatin progressed. Simvastatin-associated pulmonary toxicity is multifactorial. For patients with this drug-induced pulmonary t
Like
Comment
Share
